- Drug Manufacturers - General
- Healthcare
-
-0.46
EPS
-
-63.31
P/E
-
163B
MARKET CAP
-
5.79%
DIV YIELD
Company Overview
235 E 42ND ST,NEW YORK NY 10017,2125732323
CEO
Dr. Albert Bourla D.V.M., Ph.D.
Employess
88000
Sector
Healthcare
Industry
Drug Manufacturers - General
Website
https://www.pfizer.com
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Next Earnings Date
Oct. 29, 2024
Ex Dividends date
Sep. 03, 2024
Dividend Date
July 26, 2024
YTD Performance
-2.96%
Fiscal Year End
12-31
IPO Date
1972-06-01
Growth Rates
| (avg. rate of change) | 10 years | 5 years | 3 years | 1 year |
|---|---|---|---|---|
| Sales/Revenue | 1.27% | 1.75% | 11.76% | -41.70% |
| EPS | -19.27% | -27.52% | -32.94% | -93.20% |
| Equity | 1.55% | 7.02% | 12.07% | -6.95% |
| Cash | 2.71% | 20.16% | 16.94% | 585.82% |
| Return On Capital (ROIC) | 14.09% | 15.02% | 17.73% | 5.39% |
Debt
| year (millions) | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Short Term Debt | 10,900 | 2,940 | 2,240 | 2,700 | 16,200 |
| Long Term Debt | 61,500 | 31,900 | 34,800 | 35,600 | 36,000 |
| LT Finance Leases | 2,630 | 2,600 | 2,510 | 1,110 | 1,030 |
| Shares Outstanding | 5,640 | 5,610 | 5,600 | 5,560 | 5,570 |
| Market Cap | 162,000 | 287,000 | 331,000 | 204,000 | 207,000 |
Price
News
Forget Tech! 3 Value Stocks That Could Win Big From Rate Cuts.
1 monthInvestors usually rush into tech stocks when rate cuts loom on the horizon, as they do now. Federal Reserve Chair Jerome Powell just said that those cuts could come in September.
investorplace.com
3 Dividend Growth Stocks to Buy Hand Over Fist in August
1 monthAbbott Labs is a proven wealth builder at a fair price. Johnson & Johnson's a safe buy despite its ongoing litigation.
fool.com
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
1 monthRecently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
zacks.com
4 High Earnings Yield Value Bets as Recession Fears Resurface
1 monthUnlock your portfolio value by investing in value stocks like WDC, PDD, PFE and GOLD that display impressive earnings yield.
zacks.com
3 Cheap Stocks to Buy in August for Under $50
1 monthFinding the right stocks for investment can be a tricky game. While there are thousands of stocks to choose from, only a few can pass the test of time.
investorplace.com
3 Unstoppable Dividend Stocks Yielding More Than 4% for Income-Seeking Investors to Buy in August and Hold Forever
1 monthCVS Health benefits from multiple vertically integrated healthcare businesses. AT&T offers a yield above 5% at recent prices and could rise steadily, along with growing profits from broadband and mobile internet subscriptions.
fool.com
Volatility Spikes: 3 Low Beta Stocks to Buy
1 monthDuring periods of heightened volatility, low-beta stocks can provide a valuable layer of defense and a more balanced risk profile.
zacks.com
Pfizer: Tracking Well Above The Industry
1 monthDespite Wall Street's continued conservatism regarding its business prospects, Pfizer beat analysts' expectations for the second quarter of 2024. In addition to the raised full-year 2024 guidance, the company's remaining share repurchase authorization is $3.3 billion. Pfizer's oncology franchise sales reached $3.96 billion in the second quarter of 2024, up 25.6% year-on-year.
seekingalpha.com
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
1 monthMonday, BioNTech SE BNTX reported deeper losses in the second quarter of 2024, with an EPS loss of $(3.62) or (3.36) euros, missing the consensus of (1.89) euros and higher than (79) cents in the second quarter of 2023.
benzinga.com
Investing $100,000 in These 7 High-Yield Dividend Stocks Could Generate Over $7,000 in Annual Passive Income
2 monthsThese great sources of passive income include a business development company, three midstream energy leaders, a telecom giant, a renewable energy provider, and a big drugmaker. They offer dividend yields of between 5.5% and 9.2%.
fool.com
2 Ultra-High-Yield Dividend Stocks to Buy in August and Hold at Least a Decade
2 monthsDividend-paying stocks tend to outperform their non-dividend-paying cousins. Shares of Pfizer offer a high yield, even though sales of the company's non-COVID drugs are climbing by a double-digit annual percentage.
fool.com
Is This Decision by Pfizer Bad News for Eli Lilly?
2 monthsEli Lilly is a giant in the world of weight loss drugs, generating billions of dollars in revenue. Rival big pharma player Pfizer aims to get in on this major market.
fool.com